How Peptides Work

Receptor Binding

The biological activity of most peptides begins at the cell surface, where they interact with specific receptor proteins embedded in the plasma membrane. This interaction follows a lock-and-key (or, more accurately, an induced-fit) model: the peptide binds to a complementary site on the receptor, triggering a conformational change that activates intracellular signaling machinery. The specificity of this binding determines which cells respond to a given peptide and what downstream effects are produced.

Peptide-receptor interactions are characterized by two key properties: affinity (how tightly the peptide binds) and efficacy (how effectively binding activates the receptor). A peptide may be an agonist (activating the receptor), an antagonist (blocking the receptor without activating it), or a partial agonist (producing submaximal activation). Some peptides also act as inverse agonists, reducing the receptor's baseline activity below its constitutive level.

G Protein-Coupled Receptors (GPCRs)

GPCRs are the most common class of receptors targeted by peptide ligands, and they represent the largest family of membrane receptors in the human genome, with over 800 members. These receptors share a characteristic structure: a single polypeptide chain that crosses the cell membrane seven times (hence the designation "seven-transmembrane" or 7TM receptors), forming an extracellular ligand-binding domain and an intracellular domain that couples to G proteins.

When a peptide binds to the extracellular face of a GPCR, it induces a conformational change that propagates through the transmembrane helices to the intracellular side. This activates the associated heterotrimeric G protein (composed of alpha, beta, and gamma subunits), which then dissociates and initiates downstream signaling cascades. Different classes of G proteins (Gs, Gi, Gq, G12/13) activate different effector pathways, explaining why different peptides acting through GPCRs can produce diverse cellular responses.

Many therapeutically important peptides act through GPCRs. GLP-1 receptor agonists (like semaglutide) bind to a class B GPCR; GnRH analogs target the GnRH receptor (a class A GPCR); and opioid peptides act through mu, delta, and kappa opioid receptors, all of which are GPCRs.

Receptor Tyrosine Kinases (RTKs)

Receptor tyrosine kinases are another major class of peptide targets, particularly for growth factors and growth-factor-like peptides. RTKs are single-pass transmembrane proteins with an extracellular ligand-binding domain and an intracellular kinase domain. When a peptide ligand binds, it typically induces receptor dimerization — two receptor molecules come together, and their intracellular kinase domains phosphorylate each other (autophosphorylation). These phosphorylated residues then serve as docking sites for intracellular signaling proteins.

The insulin receptor is a prominent example of an RTK. When insulin binds, it activates the receptor's tyrosine kinase activity, leading to phosphorylation of insulin receptor substrates (IRS proteins) and activation of the PI3K/Akt pathway, which mediates glucose uptake and metabolic regulation. IGF-1 (insulin-like growth factor 1) also signals through an RTK and plays crucial roles in growth, development, and tissue repair.

Other Receptor Types

Some peptides interact with ion channel-linked receptors, directly gating the flow of ions across the cell membrane. Others bind to intracellular receptors after being transported into the cell, or interact with enzyme-linked receptors other than RTKs (such as serine/threonine kinase receptors, which mediate TGF-beta family signaling). Additionally, some peptides exert effects through non-receptor mechanisms, such as directly penetrating cell membranes (cell-penetrating peptides) or interacting with extracellular matrix components.

Signaling Cascades

Once a receptor is activated, the signal must be transmitted from the membrane to the cell's interior machinery. This occurs through a series of intracellular signaling cascades — sequential biochemical reactions that amplify, diversify, and ultimately execute the biological response. A single activated receptor can trigger a cascade that activates thousands of downstream effector molecules, a phenomenon known as signal amplification.

Three major signaling pathways are particularly relevant to peptide pharmacology:

• cAMP/PKA pathway — Activation of Gs-coupled GPCRs stimulates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates numerous target proteins and transcription factors (including CREB). This pathway mediates the effects of many peptide hormones, including GLP-1 on pancreatic beta cells (promoting insulin secretion) and GHRH on pituitary somatotrophs (promoting growth hormone release).
• MAPK/ERK pathway — This cascade is typically activated by RTKs and some GPCRs. Receptor activation leads to recruitment of Ras (a small GTPase), which activates Raf, which phosphorylates MEK, which in turn phosphorylates ERK (extracellular signal-regulated kinase). Activated ERK translocates to the nucleus and regulates gene expression involved in cell proliferation, differentiation, and survival. Growth factor peptides heavily rely on this pathway.
• JAK/STAT pathway — This pathway is activated by cytokine receptors and some growth factor receptors. Ligand binding activates receptor- associated Janus kinases (JAKs), which phosphorylate STAT (Signal Transducer and Activator of Transcription) proteins. Phosphorylated STATs dimerize and translocate to the nucleus to drive gene transcription. This pathway is critical for immune regulation and plays a role in how certain immunomodulatory peptides exert their effects.

It is important to recognize that these pathways do not operate in isolation. There is extensive cross-talk between signaling cascades, meaning a single peptide may activate multiple pathways simultaneously, producing an integrated cellular response. Furthermore, cells possess feedback mechanisms (both positive and negative) that modulate signal intensity and duration, adding additional layers of regulation.

Pharmacokinetics

Pharmacokinetics describes how the body handles a drug — its absorption, distribution, metabolism, and excretion (often abbreviated ADME). For peptides, pharmacokinetic considerations are particularly important because natural peptides are rapidly degraded in the body.

The most common route of peptide administration is subcutaneous injection. This bypasses the gastrointestinal tract (where peptides would be destroyed by digestive enzymes and stomach acid) and delivers the peptide directly into the tissue beneath the skin, from where it is gradually absorbed into the bloodstream. Subcutaneous injection provides relatively consistent absorption and is well-suited for self-administration.

Oral delivery remains a major challenge for peptide therapeutics. The harsh conditions of the GI tract — acidic pH in the stomach, abundant proteolytic enzymes (pepsin, trypsin, chymotrypsin), and the intestinal epithelial barrier — degrade most peptides before they can be absorbed. Despite these challenges, significant progress has been made. Oral semaglutide (Rybelsus) uses a permeation enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) that protects the peptide in the stomach and promotes absorption across the gastric epithelium.

Other administration routes include intranasal delivery (used for oxytocin and desmopressin, exploiting the thin nasal epithelium and direct access to systemic circulation) and topical application (used for certain wound-healing peptides like GHK-Cu). Intravenous injection provides the most rapid onset but requires clinical settings.

The concept of half-life is central to peptide pharmacokinetics. Half-life is the time required for the plasma concentration of a drug to decrease by 50%. Natural peptides often have very short half-lives — GLP-1, for example, has a half-life of approximately 2 minutes due to rapid degradation by the enzyme DPP-4. This is why so much effort goes into peptide modifications that extend half-life, enabling less frequent dosing and more consistent therapeutic effects.

Peptide Modifications

Modern peptide engineering employs a variety of chemical modifications to overcome the inherent pharmacological limitations of natural peptides. These modifications can dramatically improve stability, extend half-life, enhance receptor selectivity, and improve delivery characteristics.

• Lipidation — The attachment of fatty acid chains to a peptide is one of the most successful strategies for extending half-life. Semaglutide, for example, incorporates a C-18 fatty diacid chain that enables non-covalent binding to serum albumin. Since albumin has a half-life of approximately 19 days, this albumin binding effectively shields semaglutide from degradation and renal clearance, extending its half-life to approximately 7 days (compared to 2 minutes for native GLP-1). Liraglutide uses a similar but shorter fatty acid, achieving a half-life of approximately 13 hours.
• PEGylation — Conjugation with polyethylene glycol (PEG) polymers increases the apparent molecular size of the peptide, reducing renal filtration and shielding it from proteolytic enzymes and immune recognition. The degree of half-life extension depends on the size and architecture of the PEG moiety. PEGylation has been successfully applied to numerous peptide and protein therapeutics.
• D-amino acid substitution — Replacing one or more L-amino acids with their D-enantiomers at positions critical for protease recognition can confer significant resistance to enzymatic degradation while preserving biological activity. This approach is especially useful when the substitution site is not critical for receptor interaction.
• Cyclization — Converting a linear peptide into a cyclic structure (by forming a bond between the N- and C-termini, between side chains, or through disulfide bridges) constrains the peptide's conformation, typically improving both proteolytic stability and receptor binding affinity. Many naturally occurring peptide toxins are cyclic, reflecting the evolutionary advantage of this structural motif.
• Stapled peptides — A more recent innovation, stapled peptides incorporate a hydrocarbon bridge ("staple") across one face of an alpha-helix. This stabilizes the helical conformation, improves cell permeability, and enhances resistance to proteolysis. Stapled peptides are being actively explored as therapeutics for intracellular targets, particularly protein-protein interactions that are difficult to drug with small molecules.

Dose-Response Relationships

Understanding dose-response relationships is fundamental to peptide pharmacology. A dose-response curve plots the magnitude of a biological effect against the dose or concentration of the peptide. For most peptides, this curve follows a characteristic sigmoidal (S-shaped) pattern when plotted on a logarithmic dose scale.

The EC50 (half-maximal effective concentration) is the dose at which the peptide produces 50% of its maximum possible effect. This value is commonly used to compare the potency of different peptides or formulations. A lower EC50 indicates higher potency (less drug is needed to produce a given effect).

The therapeutic window is the range of doses between the minimum effective dose and the dose at which unacceptable toxicity begins. Peptides generally have wider therapeutic windows than small-molecule drugs, but this varies significantly among different peptides. Growth hormone secretagogues, for example, can produce markedly different effects at different doses, with low doses potentially stimulating growth hormone release while higher doses may desensitize the receptor.

A critical principle in peptide pharmacology is that "more is not always better." Many peptide receptors undergo desensitization upon prolonged or excessive stimulation — a process called tachyphylaxis or receptor downregulation. When a receptor is continuously stimulated, the cell may internalize the receptor (removing it from the surface), phosphorylate it to reduce its coupling efficiency, or reduce receptor gene expression. This is why GnRH agonists, when given continuously, paradoxically suppress gonadal function after an initial stimulatory phase — a phenomenon exploited therapeutically in prostate cancer treatment.

Biphasic dose-response relationships (also called hormetic or U-shaped responses) are observed with some peptides, where low doses produce one effect and high doses produce the opposite effect or a diminished response. These complex pharmacological profiles underscore the importance of evidence-based dosing and the danger of extrapolating from preclinical studies to human use without proper clinical evaluation.